New research suggests that higher doses of the medication semaglutide might be linked to a lower risk of developing certain mental health and neurological conditions, and this association appears to be independent of how much weight a person loses. The findings, published in npj Metabolic Health and Disease, indicate that the drug’s effects on the brain may go beyond its well-known metabolic benefits.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. Originally developed to help manage blood sugar levels in people with type 2 diabetes, these drugs mimic a natural hormone called glucagon-like peptide-1. The drug works by binding to GLP-1 receptors, which are specific protein structures located on the surface of cells, prompting the cell to behave in a certain way. While they are most famous for stimulating insulin release and slowing digestion, GLP-1 receptors are also present in the brain, including areas that control appetite and reward.
In recent years, semaglutide has become widely used as a treatment for obesity. Beyond weight management, it has also demonstrated protective effects on other organs. For example, a 2023 clinical trial found that semaglutide reduces the risk of heart attacks and strokes in people with obesity who do not have diabetes. Because of these wide-ranging health improvements, scientists want to understand the exact mechanisms at play. They question whether the positive changes in the body are a direct result of the medication acting on cells in different organs, or if they are simply a secondary benefit of carrying less body weight.
The research, led by Karthik Murugadoss and Venky Soundararajan of nference, aimed to explore these competing possibilities by examining how semaglutide relates to cognitive and mental health outcomes. By analyzing the medical histories of thousands of patients, the team hoped to see if psychiatric outcomes tracked more closely with the dosage of the medication a patient took or with the amount of weight they lost while taking it.
“Many patients report experiencing metabolic health problems and mental health conditions concurrently, yet treatment success is often summarized by kilograms or pounds lost,” said Soundararajan, founder and chief scientific officer at nference. “We wanted to understand whether Wegovy (semaglutide) dose and weight loss tell the same narrative about subsequent neurological and psychiatric diagnoses.”
The researchers conducted an observational study using a massive database of electronic health records. They identified 63,215 patients who were prescribed semaglutide and already had a documented history of a neurological or psychiatric condition. To establish a baseline for comparison, the researchers first matched these patients with individuals taking other common diabetes medications, such as metformin, making sure the groups were similar in age, sex, body mass index, and diabetes status.
Over a two-year period, patients taking semaglutide generally had lower rates of being diagnosed with new neuropsychiatric issues compared to those taking metformin. For instance, the incidence of substance-related disorders was 3.8 percent in the semaglutide group compared to 6.1 percent in the metformin group. Mood disorders were recorded in 10.5 percent of semaglutide users versus 13.2 percent of metformin users.
To dig deeper, the researchers split the semaglutide patients into groups based on two factors: the maximum dose they reached during their first two years of treatment and the maximum amount of weight they lost during that same window. The researchers then looked at the subsequent two years of medical records to see who developed new neuropsychiatric conditions, treating the two-year mark as a dividing line or “landmark.”
Achieving a higher dose of semaglutide, defined as 1.7 milligrams or more, was associated with lower rates of several mental health conditions compared to staying on a lower dose of 0.25 to 1.0 milligrams. Patients on high doses had a 29 percent lower relative risk of developing substance-related disorders during the follow-up period. They also had an 18 percent lower relative risk of mood disorders. Similar reductions were seen in rates of anxiety, neuromuscular diseases, and impulse-control disorders.
“These represent approximately 18% and 29% lower relative incidence, respectively, with absolute differences equivalent to about 23 and 14 fewer diagnoses per 1,000 people at risk,” Soundararajan told PsyPost. “Whether changing someone’s dose would produce those differences requires a randomized control trial.”
“The selectivity was striking: the association with higher doses of semaglutide did not extend across all neurological outcomes,” he added. “For example, dementia/degenerative central nervous system disease showed no significant difference between semaglutide dose groups. That reinforces why each neuropsychiatric outcome needs its own evidence and merits future studies that examine personalized precision GLP-1 medicine dosage and outcome measurements in support of each patient’s holistic health.”
When the researchers grouped patients by how much weight they lost, which ranged from less than 5 percent to more than 20 percent of their body weight, they did not see the same patterns. The amount of weight a person shed was not strongly linked to their risk of developing substance, mood, or anxiety disorders. This disconnect suggests that the psychiatric benefits associated with the drug might be driven by the medication itself rather than the physical act of losing weight.
“The weighing scale may tell only part of the story when it comes to GLP-1 medicines,” Soundararajan said. “Higher attained Wegovy (semaglutide) doses were associated with fewer subsequent mood, anxiety-related and substance-related diagnoses, without corresponding differences across weight-loss groups. This raises an important question for future research: how much can weight change alone tell us about a patient’s broader neuropsychiatric health improvement response to treatment?”
There was, however, an exception regarding cognitive and speech symptoms. These specific outcomes were more closely related to how much weight a patient lost rather than their medication dose. Patients who lost the most weight actually had slightly higher rates of recorded cognitive symptoms, rising from 2.1 percent in the group that lost the least weight to 4.7 percent in the group that lost the most. The researchers note that this does not necessarily mean the drug harms cognition. In real-world medical data, extreme weight loss can sometimes be an unintentional result of an underlying decline in health or frailty, which could also explain the increase in cognitive issues.
To provide biological context for these clinical findings, the researchers also examined publicly available genetic databases to map where the GLP-1 receptor is naturally produced in the human body. They found trace amounts of the receptor in specific brain regions, such as the hypothalamus, which helps regulate hormones and basic physical needs, and the caudate nucleus, which is involved in learning and reward processing. This genetic evidence provides a plausible pathway for the medication to interact directly with the central nervous system.
As with all research, there are a few caveats to consider. Because this was a retrospective observational study based on medical records, it cannot prove cause and effect. A major consideration is healthy-adherer bias. People who reach higher doses of a medication might just be healthier overall, more engaged with their healthcare providers, or better at taking their medication consistently. Those who experienced negative side effects early in treatment would naturally stay on lower doses or stop taking the drug altogether, which could skew the high-dose group toward individuals who already felt well.
The study also relied on medical diagnostic codes entered by doctors. These codes only capture when a condition is formally diagnosed, which often lags behind when the condition biologically began. The research was not designed to evaluate immediate psychiatric side effects that might happen right after starting the medication, nor should the findings be used to justify prescribing semaglutide specifically for psychiatric conditions. Future prospective trials, where patients are randomly assigned to different doses and closely monitored over time, will be needed to fully map out the drug’s impact on the brain.
“‘Independent of weight loss’ should be understood cautiously: comparing separate dose and weight-loss groups does not establish a direct drug effect independent of weight,” Soundararajan explained. “People who reach higher doses may differ in treatment tolerance, continuity of care and affordability, all of which could influence outcomes. We measured newly recorded diagnoses, which cannot establish recovery from an existing mental-health condition.”
“Our long-term aim is to understand which patients benefit, at what dose, and with what trade-offs across the body and brain,” he continued. “A priority is to use AI-assisted review of clinical notes to clarify actual medication use with expert physician adjudication and validation. We will similarly assess their reasons for stopping and symptom trajectories, and finally test the most credible signals with the greatest real-world evidence in prospective, gold-standard clinical trials.”
“For someone living with obesity or diabetes alongside a mental-health condition, everyday functioning, relationships and emotional well-being are central to what better health means,” Soundararajan said. “We hope this study by nference encourages future studies to measure treatment success in ways that reflect those priorities.”
The study, “Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss,” was authored by Karthik Murugadoss, A. J. Venkatakrishnan, and Venky Soundararajan.